The Authors Reply:  by Turner, Jeffrey M. & Hostetter, Thomas H.
Exploring new treatments for
chronic kidney disease
To the Editor: We read with interest the excellent review
by Turner et al.1 of both established and non-traditional
treatment options for slowing progression of chronic kidney
disease. The authors are to be commended for their
consideration of novel applications of established therapies
and metabolic targets not traditionally associated with
treatments to slow disease progression.
We wish to point out an omission in this report of a
therapy with great promise. Pentoxifylline has been studied
prospectively in more than 1000 patients enrolled in 19
clinical trials to date, with consistently positive results across
disparate populations, without apparent toxicity, and with an
excellent adverse-effect proﬁle.
Pentoxifylline is a non-speciﬁc phosphodiesterase inhibitor
with renal anti-inﬂammatory, antioxidant, and anti-ﬁbrotic
activity.2 The drug targets a distinctly different pathophysio-
logical mechanism of chronic kidney disease progression than
that of angiotensin-converting enzyme inhibitors and angio-
tensin receptor blockers.2 Pentoxifylline reduces proteinuria
and preserves kidney function among patients with diabetic
and non-diabetic chronic kidney disease, with or without
concomitant inhibition of the renin–angiotensin axis, an
important consideration given that a substantial proportion
of diabetic patients either cannot tolerate or develop
tachyphylaxis to such therapies.3,4
Health-care resources in the United States and globally will
become increasingly constrained in the years to come; it is
therefore essential that the nephrology community continues
to explore new applications of existing therapies with
demonstrated efﬁcacy for slowing the progression of a disease
that may impact X10% of the world’s adult population. We
would be foolish to do otherwise.
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The Authors Reply: We appreciate the letter from Perkins and
Yuan1 who point out that we omitted a discussion about
pentoxifylline in our recent review on treatment options for
chronic kidney disease (CKD).2 One of the challenges in writing
this piece was selecting which novel therapies should be included
in our relatively abridged discussion on this topic. This speaks to
the large number of medical therapies for CKD that have been
investigated in recent years, and the fact that very few have been
adopted into standard practice. We employed the following
criteria as a guide for selecting which agents to include in our
discussion: (1) a plausible mechanism of action supported by in
vitro and animal studies; (2) evidence of efﬁcacy and safety in
human studies, preferably randomized placebo-controlled trials;
and (3) the ever important buzz factor (admittedly a highly
subjective indicator). We concede that pentoxifylline meets
criteria 1 and 2. In terms of criterion 3, we may be able to better
answer this when the results of the PREDIAN study are known.3
With that said, it is important to acknowledge that Perkins and
Yuan’s point is well taken regarding the merits of pentoxifylline
as an effective agent for slowing CKD. This is a dynamic area of
research and in a few years, a similar review of therapies may
look very different depending on the outcomes of current studies
and the buzz that they generate.
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C4d deposits on erythrocytes
(EC4d): a new biomarker of
antibody-mediated rejection in
kidney transplantation
To the Editor: We would like to add a relevant piece of
information to the elegant review by Cohen et al.1 on C4d
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